Antibody response to different COVID-19 vaccine regimes: a review

• Autor(a) principal: Matsui, Tamires Cardoso
• Data de Publicação: 2024
• Outros Autores: de Melo, Amanda Campelo Lima, Fernandes, Maria da Conceição Rodrigues, Vasconcelos, Germana Silva, Fonseca, Marcela Helena Gambim, Araujo, Fernanda Montenegro de Carvalho
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Health Review
• Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/66181
• topic: COVID-19 vaccines; primary vaccination; heterologous; homologous; booster shot

COVID-19 pandemic initiated a race for the development of vaccines. Different technologies have been used to produce them, including inactivated whole-virus, nucleic acid, and adenovirus vector platforms. COVID-19 vaccination was initiated with two doses called “primary vaccination” which can be homologous (the same vaccine used in the first and second dose) or heterologous (different vaccines used in the first and second dose). Waning of vaccine-induced antibodies over time combined with the emerging SARS-CoV-2 variants of concern (VOCs) suggested the importance and necessity of a “booster shot” of the vaccine. The additional dose can be done with the same vaccine used in the primary vaccination (homologous booster) or vaccines can be mix-and-match (heterologous booster). Immune escape of VOCs raises the question of which is the best combination of COVID-19 vaccines. Therefore, this review summarizes the main findings of humoral response to different SARS-CoV-2 vaccination regimens.